Bedrocan bankruptcy puts medicinal cannabis supplies under pressure
The Netherlands’ only medicinal cannabis supplier has been declared bankrupt as the government seeks a new supplier.
Listen to this article
There is no audio version yet. Request one and an AI voice will read the article aloud.
Read by an AI voice.
.jpg){kind=link}
Bedrocan, based in Veendam, has been declared bankrupt after previously applying for a deferment of payment. Since 2003, the company had supplied medicinal cannabis within the Dutch government system and was reportedly the only Dutch supplier.
The Noord-Nederland District Court declared Bedrocan bankrupt on 8 October. The public insolvency file lists Mr A. Gras as the insolvency administrator. Two weeks earlier, the company had applied for a deferment of payment. It is not yet known whether there will be a restart or takeover.
Bedrocan supplied cannabis to the Bureau for Medicinal Cannabis, which handles procurement and distribution on behalf of the government. Medicinal cannabis is dispensed on prescription. According to ANP, as cited by NL Times, around 7,000 people in the Netherlands use medicinal cannabis on prescription.
The financial problems arose after the Ministry of Health ended its contract with Bedrocan earlier this year. As a result, the company could no longer supply through the existing government channel. The bankrupt company produced several varieties for the Netherlands and business customers in Denmark.
According to NL Times, the ministry says current stocks are expected to last until around the middle of 2027. At the same time, a European tender is under way for a supplier of comparable products. The government is attempting to prevent an interruption in supply.
The bankruptcy also affects the company’s employees. According to reports, Bedrocan had around 70 staff. The insolvency administrator must now map out the assets, liabilities and ongoing agreements. Whether production can continue under a new owner remains uncertain.
For patients, the bankruptcy does not automatically mean that medicinal cannabis will immediately become unavailable. According to the ministry, existing stocks and the tender provide time, but continuity depends on how quickly a new supplier is appointed and can meet quality requirements. Patients with questions about their own treatment should contact their doctor or pharmacy; this report does not provide medical advice on the matter.
One story, several perspectives
What is established
- Bedrocan has been declared bankrupt.
- The company was part of the Dutch medicinal cannabis system.
- The government is seeking a new supplier and says stocks are sufficient for the time being.
Left
Arguments The government should put security of supply and affordable access for patients at the centre. A bankruptcy in a monopoly-like chain shows that public continuity cannot be left solely to market actors.
Values Accessible healthcare, public responsibility and patient protection.
Consequences Greater government control could provide certainty, but would require public investment and could make the market less flexible.
Centre
Arguments A tender with clear quality requirements can combine continuity with efficiency. At the same time, transitional stocks and oversight must be properly arranged.
Values Reliability, medical quality and workable policy.
Consequences A careful process takes time, but reduces the risk of shortages or quality problems.
Right
Arguments Dependence on a single supplier should be reduced through greater competition and scope for imports or multiple producers. The government should primarily set the rules rather than organise the market itself.
Values Market forces, freedom of choice and limiting government risks.
Consequences More suppliers could reduce vulnerability, but international dependence and differences in quality must be managed.
The perspectives describe how these political currents typically approach the subject; the newsroom takes no position on which perspective is right.
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The core account is based on ANP reporting, a public insolvency file and information about the Dutch medicinal cannabis system. Claims about the duration of stocks and the number of users are clearly attributed to the ministry or ANP.
- confirmed Bedrocan was declared bankrupt on 8 October 2026. — The insolvency file records the bankruptcy date and court. source
- confirmed Bedrocan was the only Dutch supplier of medicinal cannabis. — This was reported by NL Times based on ANP. source
- confirmed The government expects current stocks to last until around the middle of 2027. — This expectation is attributed to the Ministry of Health. source
- uncertain Around 7,000 people in the Netherlands use medicinal cannabis on prescription. — The figure comes from ANP reporting and was not found in a separate government source. source
Editor's note
The bankruptcy and supply position have been confirmed. The exact size of the stocks and the ultimate consequences for individual patients have not yet been publicly established.Sources
- Sole Dutch medicinal cannabis firm declared bankrupt — NL Times/ANP
- Faillissement Bedrocan International B.V. in Veendam — Faillissementen.com
- Medicinale cannabis van Bedrocan — Bedrocan
- Zoeken in het Centraal Insolventieregister — Rijksoverheid
More on this in Dutch media
- NOS — „bedrocan medicinale cannabis”
- Het Parool — „bedrocan medicinale cannabis”
- Trouw — „bedrocan medicinale cannabis”